Welcome to LookChem.com Sign In|Join Free
  • or
6-Chlorouracil, a halogenated uracil derivative, is a white to off-white powder with unique chemical properties. It is known for its potential applications in various fields due to its ability to inhibit certain enzymes and its role in studying the effects of halogenation on nucleic acid base-pair stability and alkali metal ion affinity.

4270-27-3

Post Buying Request

4270-27-3 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

4270-27-3 Usage

Uses

Used in Pharmaceutical Industry:
6-Chlorouracil is used as an inhibitor of yeast alcohol dehydrogenase (ADH-H) for its potential applications in the development of therapeutic agents targeting alcohol metabolism and related disorders.
Used in DNA Repair Inhibition:
6-Chlorouracil is utilized as a potential inhibitor of DNA repair glycosylases, making it a valuable compound in the study and development of treatments for conditions related to DNA repair mechanisms.
Used in Nucleic Acid Research:
As a halogenated uracil, 6-Chlorouracil is used in studies examining the effects of halogenation on nucleic acid base-pair stability and alkali metal ion affinity. This contributes to a deeper understanding of nucleic acid structure and function, which can be applied in the development of new drugs and therapies.
Used in Synthesis of Heterocyclic Compounds:
6-Chlorouracil is employed in the synthesis of pyridinium-substituted uracils and pyridinium uracilates, which are cross-conjugated heterocyclic mesomeric betaines with separate cationic (pyridinium) and anionic (uracilate) moieties. These compounds are characterized using calculations and X-ray single crystal analyses, providing insights into their structure and potential applications in various fields.

Check Digit Verification of cas no

The CAS Registry Mumber 4270-27-3 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 4,2,7 and 0 respectively; the second part has 2 digits, 2 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 4270-27:
(6*4)+(5*2)+(4*7)+(3*0)+(2*2)+(1*7)=73
73 % 10 = 3
So 4270-27-3 is a valid CAS Registry Number.
InChI:InChI=1/C9H7BrN2/c10-9-3-1-2-7(4-9)8-5-11-12-6-8/h1-6H,(H,11,12)

4270-27-3 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • TCI America

  • (C2093)  6-Chlorouracil  >98.0%(T)

  • 4270-27-3

  • 5g

  • 690.00CNY

  • Detail
  • TCI America

  • (C2093)  6-Chlorouracil  >98.0%(T)

  • 4270-27-3

  • 25g

  • 1,990.00CNY

  • Detail
  • Alfa Aesar

  • (L01875)  6-Chlorouracil, 98+%   

  • 4270-27-3

  • 1g

  • 503.0CNY

  • Detail
  • Alfa Aesar

  • (L01875)  6-Chlorouracil, 98+%   

  • 4270-27-3

  • 5g

  • 1682.0CNY

  • Detail

4270-27-3SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 11, 2017

Revision Date: Aug 11, 2017

1.Identification

1.1 GHS Product identifier

Product name 6-Chlorouracil

1.2 Other means of identification

Product number -
Other names 6-chloropyrimidine-2,4-dione

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:4270-27-3 SDS

4270-27-3Synthetic route

2,4,6-trichloropyrimidine
3764-01-0

2,4,6-trichloropyrimidine

6-chlorouracil
4270-27-3

6-chlorouracil

Conditions
ConditionsYield
With sodium hydroxide In water for 3.5h; Reflux;98%
With sodium hydroxide In water for 2h; Reflux;98%
Stage #1: 2,4,6-trichloropyrimidine With sodium hydroxide In water for 1h; Reflux;
Stage #2: With hydrogenchloride In water pH=2 - 3;
97%
6-chloro-2,4-dihydroxypyrimidine
4270-27-3

6-chloro-2,4-dihydroxypyrimidine

6-chlorouracil
4270-27-3

6-chlorouracil

Conditions
ConditionsYield
With sodium hydroxide Reflux; Schlenk technique; Inert atmosphere;92%
6-chloro-2,4-dimethoxypyrimidine
6320-15-6

6-chloro-2,4-dimethoxypyrimidine

6-chlorouracil
4270-27-3

6-chlorouracil

Conditions
ConditionsYield
43%
With hydrogen bromide
With hydrogenchloride
6-hydroxyuracil
67-52-7

6-hydroxyuracil

6-chlorouracil
4270-27-3

6-chlorouracil

Conditions
ConditionsYield
With trichlorophosphate In acetonitrile at 120℃; for 0.166667h; Microwave irradiation;
6-chlorouracil
4270-27-3

6-chlorouracil

diaminodecane
646-25-3

diaminodecane

C18H28N6O4
87624-99-5

C18H28N6O4

Conditions
ConditionsYield
In butan-1-ol for 8h; Heating;100%
6-chlorouracil
4270-27-3

6-chlorouracil

3-chloro-aniline
108-42-9

3-chloro-aniline

6-(3-chlorophenylamino)pyrimidine-2,4(1H,3H)-dione
7269-03-6

6-(3-chlorophenylamino)pyrimidine-2,4(1H,3H)-dione

Conditions
ConditionsYield
at 170℃; for 0.333333h;99%
for 2h; Reflux;95%
In melt at 180 - 200℃;
6-chlorouracil
4270-27-3

6-chlorouracil

chloromethyl methyl ether
107-30-2

chloromethyl methyl ether

1-methoxymethyl-6-chlorouracil
228396-40-5

1-methoxymethyl-6-chlorouracil

Conditions
ConditionsYield
With lithium hydride In N,N-dimethyl-formamide at 0℃; for 0.5h;98.8%
Stage #1: 6-chlorouracil With 1,8-diazabicyclo[5.4.0]undec-7-ene In dichloromethane at 20℃; for 0.166667h;
Stage #2: chloromethyl methyl ether at 0℃; for 0.333333h;
90%
1-methyl-1H-imidazole
616-47-7

1-methyl-1H-imidazole

6-chlorouracil
4270-27-3

6-chlorouracil

3-(2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)-1-methyl-1H-imidazolium chloride

3-(2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)-1-methyl-1H-imidazolium chloride

Conditions
ConditionsYield
In chlorobenzene for 8h; Reflux;98%
In chlorobenzene for 7h; Substitution; Heating;59%
6-chlorouracil
4270-27-3

6-chlorouracil

sodium thiophenolate
930-69-8

sodium thiophenolate

6-(phenylthio)pyrimidine-2,4(1H,3H)-dione
15422-05-6

6-(phenylthio)pyrimidine-2,4(1H,3H)-dione

Conditions
ConditionsYield
In N,N,N,N,N,N-hexamethylphosphoric triamide at 90℃; for 0.05h; microwave irradiation;98%
6-chlorouracil
4270-27-3

6-chlorouracil

aniline
62-53-3

aniline

6-anilinouracil
7269-15-0

6-anilinouracil

Conditions
ConditionsYield
at 150℃; for 1h; Inert atmosphere;98%
at 160℃; for 0.333333h; microwave irradiation;95%
at 180℃; for 0.5h;91%
6-chlorouracil
4270-27-3

6-chlorouracil

6-iodo-2,4-dioxopyrimidine
4269-94-7

6-iodo-2,4-dioxopyrimidine

Conditions
ConditionsYield
With hydrogen iodide; sodium iodide at 20℃; for 24h;98%
With sodium iodide In N,N-dimethyl-formamide for 1.5h; Heating / reflux;
With potassium iodide In N,N-dimethyl-formamide for 1.5h; Heating / reflux;
6-chlorouracil
4270-27-3

6-chlorouracil

N,N'-diethyl-N-(3-methyluracil-6-yl)-p-phenylenediamine
337917-66-5

N,N'-diethyl-N-(3-methyluracil-6-yl)-p-phenylenediamine

N,N'-diethyl-N-(3-methyluracil-6-yl)-N'-(uracil-6-yl)-p-phenylenediamine
337917-67-6

N,N'-diethyl-N-(3-methyluracil-6-yl)-N'-(uracil-6-yl)-p-phenylenediamine

Conditions
ConditionsYield
With N,N-diethylaniline at 180℃; for 1h;96%
piperidine
110-89-4

piperidine

6-chlorouracil
4270-27-3

6-chlorouracil

6-piperidyluracil
73823-06-0

6-piperidyluracil

Conditions
ConditionsYield
at 100℃; for 0.25h; microwave irradiation;96%
6-chlorouracil
4270-27-3

6-chlorouracil

4-octyloxyaniline
39905-45-8

4-octyloxyaniline

6-(4-octyloxy-phenylamino)-1H-pyrimidine-2,4-dione

6-(4-octyloxy-phenylamino)-1H-pyrimidine-2,4-dione

Conditions
ConditionsYield
at 200℃; for 3h;95%
6-chlorouracil
4270-27-3

6-chlorouracil

4-(n-hexyloxy)aniline
39905-57-2

4-(n-hexyloxy)aniline

6-(4-hexyloxy-phenylamino)-1H-pyrimidine-2,4-dione

6-(4-hexyloxy-phenylamino)-1H-pyrimidine-2,4-dione

Conditions
ConditionsYield
at 200℃; for 3h;95%
6-chlorouracil
4270-27-3

6-chlorouracil

N-(8-phenylnaphthalene-1-yl)acetamide

N-(8-phenylnaphthalene-1-yl)acetamide

6-[(8-phenylnaphthalen-1-yl)amino]uracil

6-[(8-phenylnaphthalen-1-yl)amino]uracil

Conditions
ConditionsYield
at 180℃; for 0.666667h; Inert atmosphere;95%
6-chlorouracil
4270-27-3

6-chlorouracil

diphenyl diselenide
1666-13-3

diphenyl diselenide

6-chloro-5-(phenylselanyl)pyrimidine-2,4(1H,3H)-dione

6-chloro-5-(phenylselanyl)pyrimidine-2,4(1H,3H)-dione

Conditions
ConditionsYield
With dihydrogen peroxide; sodium iodide In dimethyl sulfoxide at 50℃; for 3h; Schlenk technique;95%
With potassium iodide In dimethyl sulfoxide at 20℃; for 15h; Electrolysis; Green chemistry;90%
With dihydrogen peroxide; sodium iodide In dimethyl sulfoxide at 50℃;87%
With ammonium iodide In N,N-dimethyl-formamide at 50℃; for 2h; Electrochemical reaction; Green chemistry;80%
6-chlorouracil
4270-27-3

6-chlorouracil

4-methoxy-aniline
104-94-9

4-methoxy-aniline

6-(4-methoxyphenylamino)pyrimidine-2,4(1H,3H)-dione
72255-57-3

6-(4-methoxyphenylamino)pyrimidine-2,4(1H,3H)-dione

Conditions
ConditionsYield
In diethylene glycol dimethyl ether Heating;94%
for 2h; Reflux;90%
at 180 - 200℃; for 0.166667 - 0.25h;
In propan-1-ol at 150℃; Microwave irradiation;
6-chlorouracil
4270-27-3

6-chlorouracil

methylhydrazine
60-34-4

methylhydrazine

6-(1-methylhydrazino)uracil
68558-26-9

6-(1-methylhydrazino)uracil

Conditions
ConditionsYield
In ethanol for 2h; Heating;94%
In ethanol at 100℃; for 0.166667h; Microwave irradiation; regioselective reaction;
In ethanol at 100℃; for 0.166667h; Microwave irradiation;
6-chlorouracil
4270-27-3

6-chlorouracil

m-ethylaniline
587-02-0

m-ethylaniline

6-(3-Ethyl-phenylamino)-1H-pyrimidine-2,4-dione
72255-48-2

6-(3-Ethyl-phenylamino)-1H-pyrimidine-2,4-dione

Conditions
ConditionsYield
In diethylene glycol dimethyl ether Heating;94%
6-chlorouracil
4270-27-3

6-chlorouracil

benzylamine
100-46-9

benzylamine

6-benzylaminouracil
5759-80-8

6-benzylaminouracil

Conditions
ConditionsYield
at 130℃; for 0.25h; microwave irradiation;94%
In butan-1-ol for 9h; Heating;90%
Heating;
6-chlorouracil
4270-27-3

6-chlorouracil

N-(6'-hydroxyhexyl)-3,4-dimethylaniline
189748-84-3

N-(6'-hydroxyhexyl)-3,4-dimethylaniline

6-[N-(6'-hydroxyhexyl)-3,4-xylidino]uracil
189748-85-4

6-[N-(6'-hydroxyhexyl)-3,4-xylidino]uracil

Conditions
ConditionsYield
In 1,4-dioxane; water for 15h; Reflux;94%
In 1,4-dioxane; water for 15h; Heating;63%
In 1,4-dioxane; water for 15h; Inert atmosphere; Reflux;
morpholine
110-91-8

morpholine

6-chlorouracil
4270-27-3

6-chlorouracil

6-morpholin-4-yl-1H-pyrimidine-2,4-dione
15783-46-7

6-morpholin-4-yl-1H-pyrimidine-2,4-dione

Conditions
ConditionsYield
at 100℃; for 0.25h; microwave irradiation;94%
6-chlorouracil
4270-27-3

6-chlorouracil

2-(bromomethyl)benzonitrile
22115-41-9

2-(bromomethyl)benzonitrile

2-[(6-chloro-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)methyl]benzonitrile
865758-95-8

2-[(6-chloro-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)methyl]benzonitrile

Conditions
ConditionsYield
With sodium hydride; lithium bromide In dimethyl sulfoxide; N,N-dimethyl-formamide at 20℃; for 12h;93.5%
Stage #1: 6-chlorouracil With triethylamine In N,N-dimethyl-formamide at 25℃; for 0.5h;
Stage #2: 2-(bromomethyl)benzonitrile In N,N-dimethyl-formamide at 25℃; for 8h; Reagent/catalyst; Solvent; Temperature;
79.7%
With N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 20℃;58%
6-chlorouracil
4270-27-3

6-chlorouracil

4-amino-phenol
123-30-8

4-amino-phenol

6-((4-hydroxyphenyl)amino)pyrimidine-2,4(1H,3H)-dione
72255-56-2

6-((4-hydroxyphenyl)amino)pyrimidine-2,4(1H,3H)-dione

Conditions
ConditionsYield
In diethylene glycol dimethyl ether Heating;93%
In ethanol at 150℃; for 0.5h; Microwave irradiation;75%
In propan-1-ol at 150℃; Microwave irradiation;
In ethanol at 150℃; for 0.5h; Microwave irradiation;
6-chlorouracil
4270-27-3

6-chlorouracil

para-thiocresol
106-45-6

para-thiocresol

6-chloro-5-(p-tolylthio)pyrimidine-2,4(1H,3H)-dione

6-chloro-5-(p-tolylthio)pyrimidine-2,4(1H,3H)-dione

Conditions
ConditionsYield
With dihydrogen peroxide; sodium iodide In dimethyl sulfoxide at 100℃; for 18h; Schlenk technique;93%
With dihydrogen peroxide; sodium iodide In dimethyl sulfoxide at 100℃; for 15h;83%
6-chlorouracil
4270-27-3

6-chlorouracil

1-deoxy-1-[(2,6-dioxo-1,2,3,6-tetrahydro-4-pyrimidinyl)amino]-D-ribitol
33106-48-8

1-deoxy-1-[(2,6-dioxo-1,2,3,6-tetrahydro-4-pyrimidinyl)amino]-D-ribitol

Conditions
ConditionsYield
With triethylamine In ethylene glycol at 170℃; for 0.5h;92%
for 12h; Heating;60%
With potassium hydroxide at 20℃; for 0.5h;16%
at 128℃;
6-chlorouracil
4270-27-3

6-chlorouracil

thiophenol
108-98-5

thiophenol

6-(phenylthio)pyrimidine-2,4(1H,3H)-dione
15422-05-6

6-(phenylthio)pyrimidine-2,4(1H,3H)-dione

Conditions
ConditionsYield
In pyridine for 1h; Heating;92%
With potassium carbonate In ethylene glycol Substitution;
With pyridine for 1.5h; Heating;
With pyridine Heating;
6-chlorouracil
4270-27-3

6-chlorouracil

benzyl-methyl-amine
103-67-3

benzyl-methyl-amine

6-(benzylmethylamino)uracil
21333-17-5

6-(benzylmethylamino)uracil

Conditions
ConditionsYield
at 130℃; for 0.333333h; microwave irradiation;92%
6-chlorouracil
4270-27-3

6-chlorouracil

N-ethyl-N-phenylamine
103-69-5

N-ethyl-N-phenylamine

6-(ethyl(phenyl)amino)pyrimidine-2,4(1H,3H)-dione
27281-43-2

6-(ethyl(phenyl)amino)pyrimidine-2,4(1H,3H)-dione

Conditions
ConditionsYield
at 175℃; for 0.333333h;92%
6-chlorouracil
4270-27-3

6-chlorouracil

1-aminooctadecane
124-30-1

1-aminooctadecane

6-Octadecylaminouracil
127984-96-7

6-Octadecylaminouracil

Conditions
ConditionsYield
In butan-1-ol for 5h; Heating;91%
6-chlorouracil
4270-27-3

6-chlorouracil

N-ethyl-p-tolylamine
622-57-1

N-ethyl-p-tolylamine

6-(N-ethyl-p-toluidino)uracil
77778-47-3

6-(N-ethyl-p-toluidino)uracil

Conditions
ConditionsYield
91%

4270-27-3Relevant academic research and scientific papers

Invariant and Variable Supramolecular Self-Assembly in 6-Substituted Uracil Derivatives: Insights from X-ray Structures and Quantum Chemical Study

Abdelbaky, Mohammed S. M.,Al-Wahaibi, Lamya H.,Bysani, Sai Ramya Sree,El-Emam, Ali A.,Garcia-Granda, Santiago,Percino, M. Judith,Tawfik, Samar S.,Thamotharan, Subbiah

, p. 3234 - 3250 (2021/05/29)

In this study, three new 6-(arylthio)uracil derivatives, namely, 6-(phenylthio)pyrimidine-2,4(1H,3H)-dione (1), C10H8N2O2S; 6-(p-tolylthio)pyrimidine-2,4(1H,3H)-dione (2), C11H10N2O2S; and 6-(3,5-dimethylphenylthio)pyrimidine-2,4(1H,3H)-dione (3), C12H12N2O2S, have been synthesized. Single-crystal structures of these compounds reveal an invariant molecular tape contains alternate R22(8) synthons formed by N-H···O hydrogen bonds in 1 and 3. This alternate hydrogen-bonded pattern disappeared in 2; instead, a new synthon is generated. The lattice energy calculation suggests that the methyl-substituted derivatives (2 and 3) have high stabilization energy than compound 1. The electrostatic potential map reveals the difference in the accepting tendency of the carbonyl oxygen. The Hirshfeld surface and 2D-fingerprint plots analyses demonstrate that the major intermolecular interactions come from H···O contacts in 1, and these contacts were reduced due to the presence of methyl substitutions in 2 and 3. This reduction is compensated by the increase of the same amount of H···H contacts in these structures. Further, the PIXEL energy and DFT calculations at the M06-2X-D3/cc-pVTZ level of theory were used to characterize the dimeric topology formed in structures of 1-3. The intermolecular interaction energies of dimers calculated by the PIXEL method were compared with the B97D3/def2-TZVP level of approximation. Although these molecules' crystal packing is somewhat different, the energy frameworks show similarities on the respective crystal structure's shortest axis. Furthermore, the nature and strength of various noncovalent interactions such as N-H···O, C-H···O/S/π, π···π, and a chalcogen bond of type C-S···O═C were evaluated using the Bader's quantum theory of atoms-in-molecules framework.

Pd/PTABS: Catalyst for Room Temperature Amination of Heteroarenes

Murthy Bandaru, Siva Sankar,Bhilare, Shatrughn,Chrysochos, Nicolas,Gayakhe, Vijay,Trentin, Ivan,Schulzke, Carola,Kapdi, Anant R.

supporting information, p. 473 - 476 (2018/01/28)

A mild and highly efficient catalytic amination procedure for chloroheteroarenes at ambient temperature using the Pd/PTABS catalytic system is reported. The protocol is selective for the amination of chloroheteroarenes using secondary amines such as piperidine, pyrrolidine, and several others. The exceptional mildness of the developed protocol is beneficial for the synthesis of a crucial Buparlisib intermediate as well as the formal synthesis of Alogliptin in competitive yields.

Toxoflavins and deazaflavins as the first reported selective small molecule inhibitors of tyrosyl-DNA phosphodiesterase II

Raoof, Ali,Depledge, Paul,Hamilton, Niall M.,Hamilton, Nicola S.,Hitchin, James R.,Hopkins, Gemma V.,Jordan, Allan M.,Maguire, Laura A.,McGonagle, Alison E.,Mould, Daniel P.,Rushbrooke, Mathew,Small, Helen F.,Smith, Kate M.,Thomson, Graeme J.,Turlais, Fabrice,Waddell, Ian D.,Waszkowycz, Bohdan,Watson, Amanda J.,Ogilvie, Donald J.

, p. 6352 - 6370 (2013/09/23)

The recently discovered enzyme tyrosyl-DNA phosphodiesterase 2 (TDP2) has been implicated in the topoisomerase-mediated repair of DNA damage. In the clinical setting, it has been hypothesized that TDP2 may mediate drug resistance to topoisomerase II (topo II) inhibition by etoposide. Therefore, selective pharmacological inhibition of TDP2 is proposed as a novel approach to overcome intrinsic or acquired resistance to topo II-targeted drug therapy. Following a high-throughput screening (HTS) campaign, toxoflavins and deazaflavins were identified as the first reported sub-micromolar and selective inhibitors of this enzyme. Toxoflavin derivatives appeared to exhibit a clear structure-activity relationship (SAR) for TDP2 enzymatic inhibition. However, we observed a key redox liability of this series, and this, alongside early in vitro drug metabolism and pharmacokinetics (DMPK) issues, precluded further exploration. The deazaflavins were developed from a singleton HTS hit. This series showed distinct SAR and did not display redox activity; however low cell permeability proved to be a challenge.

5-Deazaflavin derivatives as inhibitors of p53 ubiquitination by HDM2

Dickens, Michael P.,Roxburgh, Patricia,Hock, Andreas,Mezna, Mokdad,Kellam, Barrie,Vousden, Karen H.,Fischer, Peter M.

, p. 6868 - 6877 (2013/11/06)

Based on previous reports of certain 5-deazaflavin derivatives being capable of activating the tumour suppressor p53 in cancer cells through inhibition of the p53-specific ubiquitin E3 ligase HDM2, we have conducted an structure-activity relationship (SAR) analysis through systematic modification of the 5-deazaflavin template. This analysis shows that HDM2-inhibitory activity depends on a combination of factors. The most active compounds (e.g., 15) contain a trifluoromethyl or chloro substituent at the deazaflavin C9 position and this activity depends to a large extent on the presence of at least one additional halogen or methyl substituent of the phenyl group at N10. Our SAR results, in combination with the HDM2 RING domain receptor recognition model we present, form the basis for the design of drug-like and potent activators of p53 for potential cancer therapy.

Synthesis and biological evaluation of novel pyrimido[4,5-b]quinoline-2,4- dione derivatives as MDM2 ubiquitin ligase inhibitors

Dou, Xiaoxue,Li, Xin,Tao, Liu,Hu, Chunqi,Zhang, Lei,He, Qiaojun,Yang, Bo,Hu, Yongzhou

, p. 581 - 587 (2013/07/28)

A series of pyrimido[4,5-b]quinoline-2,4-dione derivatives was synthesized and evaluated for their cytotoxic activities in vitro against five human cancer cell lines. Selected compounds were tested for their MDM2 E3 ligase inhibitory activities and p53-MDM2 binding inhibitory activities. Among tested compounds, four sulfur-containing compounds (4-7) displayed enhanced cytotoxic activities and better MDM2 E3 ligase inhibitoty activities in comparison with that of HLI98c. Three compounds (4-6) showed better p53-MDM2 binding inhibitory potency with IC50 values ranging from 1.3 μM to 9.0 μM.

Diverse combinatorial design, synthesis and in vitro evaluation of new HEPT analogues as potential non-nucleoside HIV-1 reverse transcription inhibitors

Puig-De-La-Bellacasa, Raimon,Gimenez, Laura,Pettersson, Sofia,Pascual, Rosalia,Gonzalo, Encarna,Este, Jose A.,Clotet, Bonaventura,Borrell, Jose I.,Teixido, Jordi

experimental part, p. 159 - 174 (2012/09/05)

New analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) were synthesized and evaluated for their in vitro activities against HIV-1 in MT-4 cell cultures. Chemical diversity was introduced in 4 of the six positions of the core and the influence of each substituent was studied. This library was built on the basis of a rational diversity analysis with the objective of maximizing diversity and thus, the activity range with a minimum number of synthesized compounds. Among them, 2{1,2,3,1} and 2{1,2,3,4} exhibited the most potent anti-HIV-1 activities (EC50 = 0.015 μg/mL; 0.046 μM, SI >1667) and (EC50 = 0.025 μg/mL; 0.086 μM, SI >1000), respectively, which were about 71-fold and 38-fold more active than the reference compound HEPT (EC50 = 1.01 μg/mL; 3.27 μM, SI >25).

Microwave-assisted synthesis of 3-aryl-pyrimido[5,4-e][1,2,4]triazine-5, 7(1H,6H)-dione libraries: Derivatives of toxoflavin

Todorovic, Nick,Giacomelli, Andrew,Hassell, John A.,Frampton, Christopher S.,Capretta, Alfredo

experimental part, p. 6037 - 6040 (2010/11/21)

The parallel synthesis of a library of toxoflavin derivatives is described. The microwave-assisted approach involves the de novo generation of the heterocyclic scaffold and allows for facile introduction of a variety of fragments.

PROCESS FOR STRAIGHTENING KERATIN FIBRES WITH A HEATING MEANS AND DENATURING AGENTS

-

, (2010/03/02)

The invention relates to a process for straightening keratin fibres, comprising: (i) a step in which a straightening composition containing at least two denaturing agents is applied to the keratin fibres, (ii) a step in which the temperature of the keratin fibres is raised, using a heating means, to a temperature of between 110 and 250° C.

Efficient synthesis of novel 6-Phenylthio-2,4-disubstituted pyrimidines

Goudgaon,Ch, Upendar Reddy

body text, p. 443 - 448 (2010/03/04)

6-Phenylthio-2,4-disubstituted pyrimidines were prepared in five steps starting from barbituric acid. Reaction of barbituric acid with POCl3 in presence of N, N-dimethylaniline furnishes the 2,4,6-trichloropyrimidine, which on reaction with aq. NaOH under reflux yielded the 6-chlorouracil. Reaction of 6-chlorouracil with thiophenol under basic condition furnishes the 6-phenylthiouracil, which on chlorination using excess POCl3 under reflux yielded the key synthon, 6-phenylthio-2,4-dichloropyrimidine. Aromatic nucleophilic substitution reaction of 6-phenylthio-2,4-dichloropyrimidine with a oxygen nucleophile like sodium benzylate and nitrogen nucleophiles like heterocyclic primary amines, aliphatic primary amines and substituted aromatic primary amines furnished the target compounds, 6-phenylthio-2,4-disubstituted pyrimidines respectively in 40-80% yield.

Synthesis and electrochemical properties of structurally modified flavin compounds

Mansurova, Madina,Koay, Melissa S.,Gaertner, Wolfgang

supporting information; experimental part, p. 5401 - 5406 (2009/05/07)

Four structurally modified flavin compounds have been synthesized and characterized for their redox potential by chemical reduction with sodium dithionite. Besides the previously reported 1- and 5-deazariboflavin, a 7,8-didemethyl derivative and an 8-isopropylriboflavin have been obtained. The synthesis of these compounds started in all cases from appropriately substituted anilines that were condensed with the ribityl chain, followed by completion of the annealed three-ring structure. The didemethyl- and the isopropyl compounds gave absorption maxima similar to riboflavin (436 and 448 nm, respectively), whereas 1-deazariboflavin showed a bathochromically shifted absorption (λmax = 537 nm), and that of 5-deazariboflavin was hypsochromically shifted (λmax = 400 nm). The midpoint potentials (E0′) of the four modified flavin compounds were determined by potentiometric titration, using riboflavin as a reference compound. Both alkyl-modified flavins showed slightly less negative midpoint potentials, whereas both deaza compounds had more negative midpoint values compared to the reference compound. Wiley-VCH Verlag GmbH & Co. KGaA, 2008.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 4270-27-3